↓ Skip to main content

All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage

Overview of attention for article published in BMC Cancer, January 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage
Published in
BMC Cancer, January 2016
DOI 10.1186/s12885-015-2010-6
Pubmed ID
Authors

Zhifei Xu, JinJin Shao, Lin Li, Xueming Peng, Min Chen, Guanqun Li, Hao Yan, Bo Yang, Peihua Luo, Qiaojun He

Abstract

Chemotherapy is the only therapy option for the majority of AML patients, however, there are several limitations for this treatment. Our aim was to find a new chemotherapy strategy that is more effective and less toxic. MTT assays and a xenograft mouse model were employed to evaluate the synergistic activity of all-trans retinoic acid (ATRA) combined with topotecan (TPT). Drug-induced DNA damage and apoptosis were determined by flow cytometry analysis with PI and DAPI staining, the comet assay and Western blots. Short hairpin RNA (shRNA) and a RARα plasmid were used to determine whether RARα expression influenced DNA damage and apoptosis. We found that ATRA exhibited synergistic activity in combination with Topotecan in AML cells, and the enhanced apoptosis induced by Topotecan plus ATRA resulted from caspase pathway activation. Mechanistically, ATRA dramatically down regulated RARα protein levels and led to more DNA damage and ultimately resulted in the synergism of these two agents. In addition, the increased antitumor efficacy of Topotecan combined with ATRA was further validated in the HL60 xenograft mouse model. Our data demonstrated, for the first time, that the combination of TPT and ATRA showed potential benefits in AML, providing a novel insight into clinical treatment strategies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 19%
Student > Ph. D. Student 3 19%
Student > Master 2 13%
Researcher 2 13%
Student > Doctoral Student 1 6%
Other 0 0%
Unknown 5 31%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 25%
Medicine and Dentistry 3 19%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Chemical Engineering 1 6%
Computer Science 1 6%
Other 1 6%
Unknown 5 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2016.
All research outputs
#5,161,580
of 6,920,380 outputs
Outputs from BMC Cancer
#2,011
of 3,148 outputs
Outputs of similar age
#206,243
of 301,923 outputs
Outputs of similar age from BMC Cancer
#95
of 170 outputs
Altmetric has tracked 6,920,380 research outputs across all sources so far. This one is in the 14th percentile – i.e., 14% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,148 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,923 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.